United States: The Latest In The Epipen Medicaid Drug Rebate Saga – Where Are We Now?

The latest installment in the ongoing saga over EpiPen Medicaid Drug Rebates came on May 31, 2017, when Senator Charles Grassley issued a press release stating that between 2006-2016 taxpayers may have overpaid for EpiPen by as much as $1.27 billion, "far more" than the announced-but-never-confirmed or finalized $465 million DOJ settlement with Mylan.

To understand what the latest news means in the ongoing saga over EpiPen Medicaid Drug Rebates, it is important to understand how we got here. And why at the end of the day, the information Senator Grassley included in the May 31, 2016 release may be less important than the information he hinted at but omitted from the release.

History of EpiPen Classification

We have followed, with admitted insalubrious interest, the public angst over EpiPen Medicaid Drug Rebates since the late summer of 2016. That is when the media began hammering on the significant price increases for EpiPen and the lack of alternative products. Which led to questioning why EpiPen was considered a branded product for FDA purposes, but reported as a generic product for Medicaid Drug Rebate purposes?

We previously blogged about Mylan's October 2016 announcement that it had reached a $465 million settlement with the U.S. Department of Justice (DOJ) over Mylan's alleged underpayment of Medicaid Drug Rebates for EpiPen. Although Mylan stated that the settlement resolved "all" potential liability to government programs over EpiPen's classification for Medicaid Drug Rebate purposes, DOJ would not confirm the settlement. We commented that the "settlement" was likely just a handshake deal that had yet to be agreed to by all potentially impacted federal and state entities, or to be reduced to writing.

And as we blogged in January 2016, while many federal and state officials had denounced the announced settlement as inadequate and insufficient, there were many questions about the legal underpinnings of any government case against Mylan.

Under the Medicaid Drug Rebate Program, manufacturers pay higher rebate percentages on branded drugs, as opposed to generic drugs. Branded drugs are also subject to an "inflation penalty" when price increases outpace inflation. Generic drugs are exempt from the inflation penalty. But when it comes to EpiPen, in 1997 CMS issued a letter that said while the "pen" was an innovator product, since the "epi" part was epinephrine, a generic drug, the manufacturer could classify the product as a generic, subject to lower Medicaid rebates and no inflation penalty. To the best of our knowledge, that authorization has never been publicly or officially revoked.

The basis of the outrage is that for FDA purposes, EpiPen was in essence a brand drug, with limited competitor products, and "should" have been treated as a brand drug by CMS for purposes of Medicaid Drug Rebates. Had EpiPen instead been classified as a brand drug for Medicaid Drug Rebate purposes, it was theorized that its manufacturer would have been responsible for hundreds of millions of dollars in additional Medicaid Drug Rebates. Thus, it was argued that the classification and resulting rebate filings/payments could be used as the basis for a False Claims action against the manufacturer, for impliedly certifying the rebates it paid based on the product's classification were accurate.

However, this legal theory was potentially undercut by the government's own actions. It was the government itself, in the form of HHS-OIG, which first raised the question of the EpiPen classification. In a July 2009 Report on the Accuracy of Drug Categorizations for Medicaid Rebates, HHS-OIG stated that the classification of EpiPen and several other drugs as generic for Medicaid Drug Rebate purposes but brand for FDA purposes, was costing the government millions of dollars in Medicaid rebates. Even before making the Report public, HHS-OIG provided CMS with detailed information on the situation with EpiPen. But there was no public information available about what CMS did with this information.

And thanks to the U.S. Supreme Court, what CMS did, or did not do, with the information about the impact of the EpiPen classification, is significant. In a landmark June 2016 False Claims ruling, now colloquially known as the Escobar case, the Supreme Court held that information a company impliedly certifies to the government must be material to the government if that information is to be the basis of a False Claims action. In recent months, multiple courts have relied on that ruling in finding that materiality of information for False Claims purposes is not to be found in what the government says about that information, but in what the government does, or does not do, upon receiving the information.

Is Classification of EpiPen Material for False Claims Purposes?

Manufacturer price reports used for Medicaid Drug Rebate purposes are filed quarterly with CMS. It was CMS who first authorized the manufacturer to classify EpiPen as generic for Medicaid Drug Rebate purposes in 1997. And objectively, CMS had reason to question that classification and the attendant impact on Medicaid Drug Rebates in 2009, upon receipt of the 2009 HHS-OIG Report.

If CMS took no action after receiving the HHS-OIG findings in 2009, was the EpiPen classification as generic for Medicaid Drug Rebate purposes material to CMS? And if it was not material, than how can that classification be the basis for a False Claims Act case against Mylan?

Where Are We Now?

Since last fall Senator Grassley has consistently pushed government officials on two questions:

  1. What did CMS do after it received the information from HHS-OIG in 2009 questioning the EpiPen classification as generic and the resulting costs in terms of Medicaid Drug Rebate?
  2. Just how much more would the manufacturer have paid in Medicaid Drug Rebates for EpiPen from 2006-2016, if the product had been classified as brand instead of generic.

Senator Grassley's release, and his posting of a cover letter from HHS-OIG, provided a partial answer to the second question. HHS-OIG estimated the total differential in the rebate Mylan paid for EpiPen, and what it might have paid had the product been classified as brand, 2006-2017, was $1.27 billion – with an asterisk. HHS-OIG did not access or consider Medicaid Best Price reporting for EpiPen, which could impact Medicaid Drug Rebate calculations. Moreover, in recent years many states have negotiated supplemental Medicaid rebates with manufacturers, especially for more costly drugs. Those supplemental rebates should be credited to this calculation, but OIG did not access or include information on Medicaid supplemental rebates in its calculation.

Thus the $1.27 billion figure should be viewed as a ceiling not a floor, to the question of how much in Medicaid Rebates would be owed if EpiPen had been classified as brand between 2006-2016. The actual figure may be much less.

But importantly, as part of his release Senator Grassley hinted at the answer to his first question. The release acknowledges that Senator Grassley has for months "sought records of communications between CMS and Mylan about the misclassification" of EpiPen. According to Senator Grassley's May 31, 2017 press release:

"Recently, CMS provided records to the Committee that show CMS told Mylan on several occasions that the EpiPen was misclassified, yet Mylan failed to correct the classification."

However, unlike the link to the HHS-OIG cover letter, Senator Grassley did not include in his release any specifics of the CMS communications, or a link to the documentation provided by CMS. So we don't know when this communication took place. And Senator Grassley, while continuing to castigate the purported $465 million settlement from Mylan as inadequate, does criticize the federal government for "letting Mylan off the hook" and its failure "to use all available tools to hold Mylan accountable."

To date, nothing has emanated publicly from CMS mandating that EpiPen, or other similarly-situated drugs classified as generic for Medicaid Drug Rebate purposes but brand for other purposes, be reclassified. If CMS, the federal government entity charged with overseeing the Medicaid Drug Rebate Program, in fact has and continues through today to let Mylan "off the hook" for its classification of EpiPen as generic, based on CMS' actions it is hard to see how Mylan's classification of EpiPen as generic was or is "material" to CMS.

And if the classification of EpiPen as generic was not material to CMS, why should Mylan be responsible for settling any estimated underpayment of Medicaid Drug Rebates for EpiPen, let alone any false claims penalties?

We will be watching to see when, if at all, CMS acts on the classification of EpiPen and other similarly situated products. We will also be watching to see whether any False Claims action against Mylan over the EpiPen classification ever comes to fruition. Stay tuned.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Ellyn Sternfield
Rodney L. Whitlock
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.